Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study

• Published in: Drugs -- real world outcomes 2018-06, Vol.5 (2), p.109-116
• Main Authors: Kuiper, Josephina G., van Herk-Sukel, Myrthe P. P., Castellsague, Jordi, Pottegård, Anton, Berglind, Ingegärd Anveden, Dedman, Daniel, Gutierrez, Lia, Calingaert, Brian, Hallas, Jesper, Sundström, Anders, Gallagher, Arlene M., Kaye, James A., Pardo, Carolina, Rothman, Kenneth J., Perez-Gutthann, Susana
• Format: Article
• Language: English
• Subjects: Age; Clinical medicine; Cohort analysis; Epidemiology; Internal Medicine; Medicine; Medicine & Public Health; Original; Original Research Article; Patients; Pharmacology/Toxicology; Pharmacotherapy; Population; Population-based studies; Practice research; Prescription drugs; Prescriptions; Public health; Regulatory approval; Skin; Skin cancer
• ISSN: 2199-1154; 2198-9788
• DOI: 10.1007/s40801-018-0133-1

Background Despite the concerns about a potential increased risk of skin cancer and lymphoma with the use of topical tacrolimus and pimecrolimus, no population-based studies have given an overview of the use of these drugs in Europe. Objective To assess the use of topical tacrolimus and pimecrolimus in children and adults in Europe. Methods Multicentre database cohort study comprising data from the Netherlands, Denmark, Sweden and the UK. We analysed users of topical tacrolimus and pimecrolimus starting from the date of first availability (between 2002 and 2003) or start establishment of the prescription database in Sweden (2006) through 2011. Use was assessed separately for children (≤ 18 years) and adults. Results 32,052 children and 104,902 adults were treated with topical tacrolimus, and 32,125 children and 58,280 adults were treated with topical pimecrolimus. The number of users increased rapidly after first availability, especially for topical tacrolimus. Topical tacrolimus was more frequently used in all countries except Denmark. For both drugs, there was a decrease in users after 2004 in the Netherlands and Denmark and after 2005 in the UK, especially among children. This decrease was largest in Denmark. The decrease in the number of users was temporary for topical tacrolimus, while use remained relatively low for topical pimecrolimus. Conclusions The number of topical tacrolimus and pimecrolimus users increased rapidly after regulatory approval. A transient reduction in topical tacrolimus use and a persistent reduction in topical pimecrolimus use was seen after 2004 in the Netherlands and Denmark and after 2005 in the UK.